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Abstract
Background: Smokers need effective support to maximise the chances of successful quit attempts. Current
smoking cessation medications, such as nicotine replacement therapy (NRT), bupropion, nortriptyline or varenicline,
have been shown to be effective in clinical trials but are underused by smokers attempting to quit due to adverse
effects, contraindications, low acceptability and/or high cost. Cytisine is a low-cost, plant-based alkaloid that has
been sold as a smoking cessation aid in Eastern Europe for 50 years. A systematic review of trial evidence suggests
that cytisine has a positive impact on both short- and long-term abstinence rates compared to placebo. However,
the quality of the evidence is poor and insufficient for licensing purposes in many Western countries. A large, well-
conducted placebo-controlled trial (n = 740) of cytisine for smoking cessation has recently been published and
confirms the findings of earlier studies, with 12-month continuous abstinence rates of 8.4% in the cytisine group
compared to 2.4% in the placebo group (Relative risk = 3.4, 95% confidence intervals 1.7-7.1). No research has yet
been undertaken to determine the effectiveness of cytisine relative to that of NRT.
Methods/design: A single-blind, randomised controlled, non-inferiority trial has been designed to determine
whether cytisine is at least as effective as NRT in assisting smokers to remain abstinent for at least one month.
Participants (n = 1,310) will be recruited through the national telephone-based Quitline service in New Zealand
and randomised to receive a standard 25-day course of cytisine tablets (Tabex
®) or usual care (eight weeks of NRT
patch and/or gum or lozenge). Participants in both study arms will also receive a behavioural support programme
comprising an average of three follow-up telephone calls delivered over an eight-week period by Quitline. The
primary outcome is continuous abstinence from smoking at one month, defined as not smoking more than five
cigarettes since quit date. Outcome data will also be collected at one week, two months and six months post-quit
date.
Discussion: Cytisine appears to be effective compared with placebo, and given its (current) relative low cost may
be an acceptable smoking cessation treatment for smokers, particularly those in low- and middle-income countries.
Cytisine’s ‘natural’ product status may also increase its acceptability and use among certain groups of smokers,
such as indigenous people, smokers in countries where the use of natural medicines is widespread (e.g. China,
India), and in those people who do not want to use NRT or anti-depressants to help them quit smoking. However
it is important to ascertain the effectiveness of cytisine compared with that of existing cessation treatments.
Trial registration: Australian New Zealand Clinical Trials Registry (ACTRN12610000590066)
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One in two smokers will die of a smoking-related dis-
ease, and half of those who die as a direct consequence
of smoking will die in middle age [1]. Smoking (combin-
ing active and passive smoking) is responsible for
approximately 18% of all deaths in New Zealand [2], an
island nation (population 4.3 million) in the Southwest
Pacific. Smoking contributes substantially to the life
expectancy differential between Māori (indigenous New
Zealanders who comprise 15% of the national popula-
tion) and non-Māori [3]. Stopping smoking at any age
reduces smoking related risks and increases life expec-
tancy [4]. Effective treatments to aid smoking cessation
have clear individual and public health benefits and pro-
vide the most efficient use of health care resources at a
population level [5].
Use of pharmacological treatments such as nicotine
replacement therapy (NRT), bupropion and nortriptyline
approximately doubles a smoker’sc h a n c eo fl o n g - t e r m
abstinence [6,7]. Varenicline appears superior to bupro-
pion and at least doubles the long-term chances of quit-
ting compared to placebo [8]. The success of a smoking
cessation product depends on its availability and accept-
ability to smokers as well as its efficacy. In 2009 in New
Zealand, among smokers aged 15-64 years who had
made a recent quit attempt, 22% had used NRT and
4.6% had used a prescription medicine (e.g. varenicline)
to support their quit attempts [9]. Many smokers are
misinformed about the risks of nicotine and are there-
fore hesitant to use NRT [10,11]. Bupropion and nor-
triptyline have a number of adverse effects and
contraindications [7], which may contribute to their
relatively poor uptake among smokers trying to quit.
Given these issues new pharmacological treatments to
help people quit smoking need to be identified - one
such product is cytisine.
Cytisine is an alkaloid found in plants such as the
Golden Rain tree (Cytisus laburnum) [12] and the New
Zealand Kowhai tree (Sophora tetraptera)[ 1 3 ] .S u c h
plants are considered to be poisonous to humans, with
the alkaloids they contain (including cytisine) considered
to be the toxic components. However, an oral tablet
form of cytisine, Tabex
®, has been marketed by
Sopharma (Bulgaria) as a smoking cessation aid since
the 1960’s. When used at its therapeutic dose (1.5-9 mg
of cytisine per day) trial data indicates that Tabex
® is
well tolerated with few adverse effects, similar to those
seen with NRT use [14-17]. Furthermore, West et al.
(2011) report that a recent Periodic Safety Update pro-
vided to European authorities, did not identify any safety
signals for cytisine (based on a sample of more than 7
million exposed persons) [17]. Cytisine overdose has
been reported and is likened to nicotine intoxication,
with symptoms including nausea, vomiting, pupil
dilation, tachycardia, general weakness, clonic convul-
sions, and respiratory paralysis [18]. Cytisine is off-
patent and currently relatively inexpensive compared
with most other pharmacological cessation products on
the market. Cytisine may also be attractive to those peo-
ple who prefer not to use a nicotine-based product or
antidepressants to help them quit smoking. A recent
qualitative study looking at cytisine’s potential to be
used as a healing remedy by traditional indigenous hea-
lers to help their people stop smoking, suggests that
cytisine would be very attractive if it were marketed in a
culturally appropriately manner [19].
Like its analogue varenicline, cytisine acts as a partial
agonist of the nicotinic acetylcholine receptor [8]. It is
thought to aid smoking cessation by reducing the
reward and satisfaction associated with smoking [20].
Despite having been used by hundreds of thousands of
smokers throughout Eastern Europe [20], cytisine is
rarely mentioned in English-language literature and
there are only limited data from clinical trials to support
its use. A systematic review [14] identified three pla-
cebo-controlled trials of cytisine and all were published
in non-English language journals. All three trials were
conducted over 30 years ago in Eastern Europe prior to
the advent of good clinical practice (GCP) guidelines
and all suffered from weaknesses in study design and
reporting of results [21-23]. The authors of the review
combined data from these trials in a meta-analysis and
reported a clear effect on smoking abstinence at 3-8
weeks (Odds Ratio [OR] 1.93, 95% confidence interval
[CI] 1.21 to 3.06) and at 3-6 months (OR 1.83, 95% CI:
1.21 to 2.99) for cytisine compared to placebo [14].
Although these findings appear promising, the three
trials were not conducted to GCP standards and thus
regulatory authorities in many countries are unlikely to
accept the evidence for licensing purposes. Data from at
least two appropriately powered placebo-controlled clin-
ical trials run to GCP standards are required to satisfy
regulatory authorities in most western countries. Since
the review was published, two additional placebo-con-
trolled trials of cytisine have been published and both
confirm earlier findings [16,17]. The first trial was well-
conducted, with randomisation, double-blinding and
clear outcome measures, but was underpowered (n =
171). The authors reported an OR for cessation at 26
weeks of 8.93 (95% CI: 1.06 to 75.28). A second trial
had a large sample size (n = 740), was conducted to
GCP standards and reported 12-month continuous
abstinence rates of 8.4% in the cytisine group compared
to 2.4% in the placebo group (relative risk=[RR] 3.4,
95% CI 1.7-7.1) [17].
Following on from the recently published placebo-
controlled trial by West et al. (2011) [17], an appropriate
research question to now answ e ri sh o wt h ee f f i c a c yo f
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from a policy and funding perspective to help decide
whether to use cytisine as a first or second line agent
for smoking cessation treatment or whether to publicly
fund the drug. Based on the systematic review men-
tioned above, the expected difference in efficacy between
cytisine (OR = 1.83, 95% CI 1.21 to 2.99)[14] and NRT
(OR = 1.74, 95% CI 1.64 to 1.86) [6] is too narrow to
feasibly conduct a head-to-head superiority trial. We
therefore propose conducting an o n - i n f e r i o r i t yt r i a lt o
demonstrate whether cytisine is at least as effective as
NRT at increasing quit rates in dependent smokers
motivated to quit.
Objectives
The primary objective of the trial is to determine how
effective cytisine is at increasing quit rates at four weeks
after randomisation. This study has three main hypoth-
eses: 1) that cytisine plus behavioural support is at least
as effective as usual care (NRT plus behavioural sup-
port) at increasing quit rates; 2) that cytisine plus beha-
vioural support is at least as effective as usual care
(NRT plus behavioural support) at reducing the severity
of withdrawal symptoms; and 3) that cytisine is an
acceptable smoking cessation treatment to Māori, Pacific
and non-Māori non Pacific alike.
Methods/Design
Study design
This study is a parallel group, single-blind, non-inferior-
ity, randomised controlled clinical trial.
Study population
The study population will be registered and eligible call-
ers to the national toll-free smoking cessation helpline
[Quitline] in New Zealand.
Inclusion criteria
Participants will be smokers from throughout New Zeal-
and who want to stop smoking, are at least 18 years of
age, are able to provide verbal consent, and have access
to a telephone.
Exclusion criteria
Pregnant women and women who are breastfeeding will
be excluded from the trial. People will also be excluded
from the trial if they meet any of the following criteria:
current users of pharmacological cessation therapies (e.
g. NRT, buproprion, clonidine, nortriptyline or vareni-
cline); current clients of another smoking cessation pro-
gramme or cessation study; they have uncontrolled high
blood pressure (> 150 mmHg systolic, > 100 mmHg dia-
stolic), schizophrenia or phaeochromocytoma; they have
had a myocardial infarction, angina, severe cardiac
arrhythmia or a stroke in acute phase within the last
two weeks. The medical conditions above are listed con-
traindications for the use of cytisine, NRT patch, gum,
and lozenge. A number of disease conditions are known
where precautions for the use of NRT products are indi-
cated, and will be assessed in each participant by
researchers prior to randomisation. These include:
severe cardiovascular disease (occlusive peripheral arter-
ial disease, cerebrovascular disease, stable angina pec-
toris, and uncompensated heart failure) and vasospasm,
uncontrolled hypertension, renal or hepatic impairment,
active duodenal ulcers and gastric ulcers.
Randomisation: allocation concealment and sequence
generation
All participants will be assigned a unique registration
number allocated by a central computer following
details submitted on a web-based form. This number
will be used to identify each randomised participant
who has consented to take part. Participants will be ran-
domised by computer, with stratified minimisation by
sex, ethnicity (Māori, Pacific, non-Māori non-Pacific),
and level of nicotine dependence (> 5 points, ≤ 5 points
on the Fagerström Test for Nicotine Dependence
[FTND] questionnaire [24]), to ensure a balance in these
key prognostic indicators between the intervention and
control groups. The randomisation sequence will be
concealed from all research staff and will not be able to
be manipulated.
Blinding
D u et ot h en a t u r eo ft h ei n t e r v e n t i o no n l ys i n g l eb l i n d -
ing (of researchers, not of participants) is possible.
Members of the trial steering committee, management
committee, and other study team members (with the
exception of the project co-ordinator and the Quitline
senior research manager) will remain blinded to treat-
ment allocation until the code is broken (namely, after
the last follow-up call is completed and the data
recorded). The project co-ordinator will not be blinded
as they will be responsible for distributing the cytisine
to participants. The senior research manager and
research assistants based at Quitline will not be blinded
to treatment allocation, as they are required to know
which group each participant has been allocated to in
order to conduct the scheduled follow-up calls.
Study intervention
Participants will be randomised to receive a course of
cytisine [intervention] or usual care [control] (Figure 1).
All participants will also receive an eight week, tele-
phone-based, behavioural support programme delivered
by Quitline advisors. Quitting support generally involves
an average of three follow-up telephone calls, each
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want to receive this support, they are not scheduled and
callers are advised that they can phone Quitline at any
time for support.
Intervention
Participants in the intervention arm will receive a 25-
day course of cytisine tablets (Tabex
®) delivered by
courier. Participants will be asked to reduce their smok-
ing over the first four days of treatment so that they are
not smoking at all by the fifth day, which will be their
designated Quit date. Participants will follow the dosing
regimen as recommended by the manufacturer, namely:
￿ Days 1-3: 1 tablet every 2 hours through the waking
day (up to six tablets per day)
￿ Days 4-12: 1 tablet every 2.5 hours (up to 5 per day);
designated Quit date is day 5
￿ Days 13-16: 1 tablet every 3 hours (up to 4 per day)
￿ Days 17-20: 1 tablet every 4-5 hours (3 per day)
￿ Days 21-25: 1 tablet every 6 hours (2 per day)
As part of an automated process at Quitline, all parti-
cipants, including those in the treatment group, will be
sent Quitcards, which may be redeemed for subsidised
NRT (see below for more detail). However, participants
will be asked to use the cytisine tablets sent to them for
the first 25 days, and not the NRT. Participants will be
told to redeem their vouchers for NRT only if they are
smoking one month after their trial quit date or require
on-going cessation support after they have finished the
course of cytisine.
Control
Participants allocated to the control arm of the trial will
be asked to stop smoking completely on their chosen
Quit date and will be supported by Quitline in the usual
way for eight weeks, with counselling/advice and NRT
in the form of a patch and/or gum or lozenge. Current
standard cessation practice at the New Zealand Quitline
(as at November 2011) is as follows (other cessation
providers in New Zealand do not follow the process
outlined here): Quitline issues by post, two (or some-
times three) four-week Quitcards (with a 90 day expiry).
Participants take each four-week Quitcard to a pharma-
cist in exchange for subsidised patches and/or gum or
lozenges (NZ$3-6 per item per four-week course of
NRT). The strength of NRT patch and/or gum or
lozenges to be used by each participant is determined
by the Quit advisor (as per their dosage guidelines) as to
the degree of each person’s nicotine dependency.
Baseline assessments
Participants from throughout New Zealand will call
Quitline seeking advice and wishing to enrol in the
Quitline smoking cessation programme. A Quit advisor
from Quitline will undertake the standard Quitline
assessment. A list of those individuals who indicate
“yes” to taking part in research will be transferred from
the Quitline database to the research assistants based at
Quitline. The research assistants will attempt to make
contact with people on the list. Those contacted will be
Treatment group
Control group
Baseline and 
randomisation
Quit date
1 month 2 months
- 4 days
Day 0
NRT patch and/or gum or lozenge
Usual behavioural support
20 days
Cytisine  tablets (Tabex
®)
Primary
end-point
NRT patch and/or gum or lozenge
(if required)
Other
end-points
Usual behavioural support
Reduce 
smoking
6 months
Other
end-points
Figure 1 Trial schematic. Footnote: NRT = Nicotine replacement therapy.
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to take part in the study. If the potential participant
indicates that they are interested, they will be consented
and asked for demographic data (age and sex) and
checked to see if they meet the inclusion criteria for the
trial. For those who do meet the inclusion criteria,
further details will be collected about the participant’s
ethnicity and level of nicotine dependence (as deter-
mined by the FTND [24]) and they will be randomised.
Data from this initial assessment will then be electroni-
cally transferred (securely) to the Clinical Trial Research
Unit’s Oracle database. The research assistant will then
collect the following baseline data from each participant
over the telephone.
￿ Demographic information: Socio-economic position
based on education.
￿ Smoking history: Age when started, number of
cigarettes smoked per day, number of years as regu-
lar smoker, number of previous unsuccessful
attempts to give up in past 12 months and the
method used, type of cigarettes smoked per day (e.g.
roll-your-own or factory-made) and usual brand/
pack size (and how long pack lasts for roll-your-own
users).
￿ Other smoking related information: Self-rated
chances of quitting, household smoking, and smok-
ing in cars. Satisfaction with smoking will also be
assessed at baseline (and at follow-up), using the
modified Cigarette Evaluation Questionnaire
(mCEQ) [25]. This questionnaire was used in the
one trial (n = 746) that has compared the effect of
varenicline versus NRT on quit rates [26]. This trial
found varenicline use resulted in significantly less
satisfaction with smoking compared to NRT use, in
those participants that did not quit smoking. It is
important to determine if cytisine, given it is a simi-
lar class of drug to varenicline, has an analogous
effect.
￿ Concomitant medication: Information about types
of medication currently used will be collected.
￿ The physical signs and symptoms associated with
withdrawal: Measured using the Mood and Physical
Symptoms Scale (MPSS) [27].
￿ Alcohol use and abuse: Data from both animal [28]
and human studies [29] have shown that varenicline
can also reduce alcohol consumption. Given cytisine
is a similar class of drug as varenicline it may have
an analogous effect on alcohol use, although to date
no such effect has been published. For this reason,
information about alcohol use and abuse will be col-
lected in this study, using the Alcohol Use Disorders
Identification Test-consumption subscale [AUDIT-
C], a screening tool that helps to identify people
who are hazardous drinkers or have an active alco-
hol use disorder (including alcohol abuse or depen-
dence) [30].
Outcome measures
Primary outcome
The proportion of participants that have stopped smok-
ing, one month post-quit. ‘Stopped smoking’ will be
defined as self-report of having smoked not more than
five cigarettes in the one month after the Quit date
(continuous abstinence).
Secondary outcome
The following secondary outcome measures will be
assessed at one week and one month after the Quit date
in the treatment group only:
￿ Information related to the use of cytisine: Partici-
pants will be asked for their views on the use of cyti-
sine as a cessation aid (i.e. whether they would
recommend the treatment to another smoker and
whether they liked or disliked using the product).
￿ Participants’ treatment compliance: Self-reported
pill counts (also asked at two months), concomitant
cytisine and NRT use (also asked at two months),
early stopping of cytisine and reasons why.
The following secondary outcome measures will be
assessed in all participants at one week and one, two
and six months after the Quit date:
￿ The physical signs and symptoms associated with
withdrawal: Assessed using the MPSS [27] in absti-
nent smokers, measured at one week, one month
and two months only.
￿ Self-rated chances of quitting: Measured at one
week, one month and two months only.
￿ Seven-day point prevalence: The proportion of partici-
pants that have stopped smoking, defined as self-report
of having smoked no cigarettes (not even a puff) in the
past seven days. Measured at every time point.
￿ Continuous abstinence: The proportion of partici-
pants that have stopped smoking, defined as self-
report of smoking not more than five cigarettes
from the Quit date. Assessed at every time point.
￿ Use of cigarettes: If the participant is smoking at
any time point, the following outcomes will be
assessed: number of cigarettes smoked per day; pro-
portion of participants who have significantly
reduced their daily smoking level (defined as redu-
cing consumption by at least 25% in terms of num-
bers of cigarettes per day or weight of loose tobacco
per day); smoking satisfaction (measured using the
mCEQ).
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use of any NRT (including type, dosage, flavour, and
frequency of use) at every time point.
￿ Use of non-NRT methods of cessation: Participants
will be asked about their use of non-NRT methods
of cessation such as buproprion, clonidine, nortripty-
line, varenicline, acupuncture etc, measured at two
and six months only.
￿ Alcohol use and abuse: Measured using the
AUDIT-C. Measured at one and two months only.
￿ Adverse events: Information regarding any adverse
events and whether they are considered to be related
to treatment will be collected at every time point.
￿ Cost information: Cost outcomes will be derived
from known costs of the various products, and will
include cost per quitter and cost per person redu-
cing their daily cigarette consumption. The tobacco
expenditure savings to individual smokers will also
be calculated using data on the daily amount
smoked prior to quitting and the price of the parti-
cular products smoked.
￿ Concomitant medication: Collected at every time
point.
Sample size
A sample size of 1,310 (655 in each group) is required
for this trial. Internal Quitline service evaluations and
previous findings from a cessation trial conducted by
the Clinical Trials Research Unit have established that
the average four week quit rate in people receiving usual
care through Quitline is approximately 50% [31,32]. A
n o n - i n f e r i o r i t ym a r g i no fd i f f e r e n c eb e t w e e nt h eg r o u p
proportions was set at 5% (i.e. the quit rates in the cyti-
sine treatment group will be no worse than 5% less than
the rate in the NRT active control group). A sample size
of 1,310 will be sufficient to confer 90% power at the
one-sided significance level of 0.025 using a binomial
test for equivalence. The true four week quit rate in
those who receive cytisine was assumed to be 55%,
which is midway between the estimated efficacy of vare-
nicline (60%) [8] and NRT [6]. The required sample size
incorporates a 20% inflation factor to allow for a suffi-
ciently large dataset to evaluate the intervention based
on both the intention to treat as well as the per protocol
population. The sample size is adequately powered to
also evaluate the non-inferiority of cytisine on two
month quit rates. Recruitment will take approximately
18 months based on previously run Quitline trials
[32,33], and will aim for a minimum of 25% of partici-
pants to be Māori and 15% to be Pacific peoples. The
sample size will allow the consistency of effects for
Māori and Pacific peoples compared to non-Māori non-
Pacific to be assessed.
Withdrawal criteria
Should participants require discontinuation of study
treatment for any reason (see below), or if they elect to
cease taking treatment, follow-up calls and data collec-
tion will continue as scheduled as if they were continu-
ing with the randomised treatment. Participants may
have the study treatment withdrawn if one or more of
the following occurs:
￿ The participant makes a voluntary decision to with-
draw from follow-up, or from the treatment.
￿ The participant has any serious clinical adverse event,
concurrent illness, or other medical condition that indi-
cates to the principal investigator that continued treat-
ment with the study treatment is not in the best interest
of the participant. The study treatment will be withdrawn
if the participant develops any life threatening or ser-
iously disabling illness or is admitted to hospital.
￿ The participant becomes pregnant during the course
of the trial. Participants will be advised to stop taking
their allocated treatment and discuss on-going use of
smoking cessation products with their general practi-
tioner or lead maternity caregiver.
￿ The principal investigator feels that it is in the best
interests of the participant.
￿ The study is terminated.
If the participant discontinues treatment due to a ser-
ious adverse event, the participant will be followed until
the event resolves or there is a return to a clinically
acceptable medical status. Participant deaths or serious
adverse events, which occur within 30 days of disconti-
nuation, will be reported to the project co-ordinator.
Data management
The design and management of all databases associated
with this trial will be undertaken by the data management
and information technology groups at the Clinical Trials
Research Unit. The databases will be constructed in Ora-
cle and internet database entry at Quitline (undertaken by
the research assistants) will be via their in-house Filemas-
ter system, from which the Unit receives hourly updates.
Uploads will be stored in the Unit’s Oracle database and
linked to the electronic Case Record Form (CRF) data
where applicable. Validation rules for each CRF will be
specified by the project co-ordinator, in association with
the senior data manager. These rules will include range
checks so that inaccuracies in data collection can be iden-
tified early. A query will be raised as soon as any values
are entered that are outside the allowed range or if data
are missing. The research assistants at Quitline will amend
the form as soon as a query is raised.
Data monitoring
An independent Data Safety and Monitoring Committee
(DSMC) will be established for this trial. Members of
Walker et al. BMC Public Health 2011, 11:880
http://www.biomedcentral.com/1471-2458/11/880
Page 6 of 9the committee will have no conflicts of interest and will
not be directly involved with the trial. The DSMC will
draw up their own terms of reference and will be free to
review any information or study process in addition to
the reviews of safety data. The study statistician will
provide the committee with reports on safety data. An
independent person will also monitor Quitline and the
Clinical Trials Research Unit during the trial to ensure
that the study protocol is adhered to. At Quitline the
monitor will audit every randomised participant’s
records and ensure that study documentation is up-to-
date and record keeping meets protocol and regulatory
requirements. The monitor will visit Quitline early on
during the study (after ten participants have been rando-
mised), at study close-out and twice during the course
of the trial. The monitor will audit the Clinical Trials
Research Unit every three months to see that handling
of the study medication is appropriate and correct docu-
mentation is kept.
Data analysis
A senior biostatistician at the Clinical Trials Research
Unit was involved in the sample size estimation, wrote
the statistical analysis plan agreed upon by all members
of the Steering Committee specifying ap r i o r iall ana-
lyses to be undertaken. Data from the trial will be
entered into an Oracle database and all statistical ana-
lyses will be performed using SAS version 9.2 (SAS
Institute Inc. Cary NC), and R. No interim analyses will
be undertaken.
Baseline characteristics
Socio-economic status, smoking information, and mood
and physical symptoms associated with withdrawal will
be summarised and descriptive summary statistics pro-
vided. Since any differences between randomised groups
at baseline could only have occurred by chance, no for-
mal significance testing will be conducted.
Treatment effects
Non-inferiority will be evaluated by testing whether the
lower bound of the 95% CI for difference in quit rates
excludes a 5% difference. In particular, the proportion
of participants that have been continuously abstinent at
four weeks for both groups and the associated two-
sided 95% CI for the difference will be estimated. Non-
inferiority of cytisine over NRT will be accepted if the
lower bound of the 95% CI around the estimated differ-
ence in the primary endpoint event rates lies above 5%.
The primary analyses will be carried out on an inten-
tion-to-treat basis where participants lost to follow-up
will be presumed to be smoking. However, it is increas-
ingly recognised that non-inferiority studies should also
be evaluated against a per protocol population defined
on the basis of compliance, protocol violations, and
missing data [34,35]. Both sets of results are important
and will be considered when assessing the study objec-
tive. In the case that non-inferiority is evident, assess-
ment as to whether cytisine is superior to NRT will be
carried out using the same approach but comparing to
a zero difference and applied to the intention to treat
population.
Chi-squared analyses comparing the proportion of
participants that have been continuously abstinent by
treatment group, and incidence rates, RR, risk differ-
ences and 95% CI will be calculated. Subsequent sec-
ondary analyses involving adjustment for baseline
covariates including stratification factors will be under-
taken using logistic regression. The consistency of
effects for Māori, Pacific peoples, and non-Māori non-
Pacific will be assessed using tests for heterogeneity.
The distribution of all continuous endpoints will be
assessed for normality and skewed data will be subjected
to an appropriate transformation before analysis. The
change from baseline in symptoms of nicotine withdra-
wal, AUDIT-C and number of cigarettes smoked per
d a yw i l lb ea n a l y s e du s i n grepeated measures models
and adjustment for baseline value.
A pre-analysis review will be conducted before the pri-
mary analyses. The purpose of this review is to establish
rules for a per protocol analysis and to reconsider the
analysis plan (e.g., adjustment for potential confounders)
in light of recent research. Any amendments (and the
rationale) will be justified and documented in the statis-
tical analysis plan. A per protocol analysis involves look-
ing at the major protocol violations such as cross-over
treatments, withdrawals and lost to follow-up. The per
protocol population will consist of all randomized
patients who have complied with the treatment allo-
cated, were not lost to follow-up, and who do not have
major protocol deviations pertaining to eligibility or the
assessment of the treatment difference.
Cost analyses
If the primary outcome of the trial is positive then cost
analyses will be undertaken. Cost outcomes will include
cost per quitter and cost per person reducing their daily
cigarette consumption. These data will then be com-
p a r e dw i t hN e wZ e a l a n dd a t af r o mQ u i t l i n ea n do t h e r
NRT service providers, in addition to information from
various international studies. This modelling will take a
health sector perspective. However, the tobacco expen-
diture savings to individual smokers will also be calcu-
lated (for those who quit and cut down) to give a more
societal perspective on the benefits (especially to low-
income smokers). This calculation will use data on the
daily amount smoked prior to quitting and the price of
the particular products smoked. For those who cut
down their consumption by a significant margin (i.e.
25% or more), the cost per person reducing their daily
cigarette consumption will be calculated.
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All randomised participants who receive at least one
dose of intervention or control treatment will be
included in the planned analyses. Comparison of the fre-
quency of treatment withdrawal between the interven-
tion and the control group will be tested using Chi-
square statistics. The numbers of participants disconti-
nuing treatment prematurely for any reason will be
summarised by treatment group and by reasons for dis-
continuation. The incidence of all suspected serious
adverse treatment reactions will be summarised by treat-
ment group.
Ethics
Ethics approval has been granted by the National Multi-
Regional Ethics Committee (Ethics number MEC/10/08/
078). Maintenance of confidentiality and compliance
with the Privacy Act will be emphasised to all study par-
ticipants. Participation in the study is entirely voluntary.
Verbal consent will be obtained at the time of contact
with Quitline, however a written consent form and
patient information sheet will be posted out to partici-
pants for their information. Data will be entered, stored
and backed-up in a secure manner via the Unit’si n t e r -
net data management system. Participants will be
acknowledged in all publications and presentation of the
results, and will receive a copy of the trial findings writ-
ten in lay terms.
Discussion
Primary outcome assessment
The non-inferiority trial design precludes us from hav-
ing a primary outcome based on six month quit rates.
Loss to follow up and treatment non-compliance tends
to reduce observed differences in treatment effect,
which in non-inferiority trials biases findings away from
the null. Later assessments are more likely to suffer
from loss to follow up and treatment non-compliance,
particularly as participants in the intervention group
may use NRT after they have completed their 28 day
course of cytisine if they feel it necessary to support
their on-going quit attempt. Removing these participants
from per protocol analysis of six month quit rates is
likely to significantly reduce the power of the study.
Instead the primary outcome will be based on a one
month assessment of quit rates, with six month quitting
variables collected as secondary outcomes.
Validation of smoking abstinence
No validation of self-reported smoking status will be
undertaken in this trial. Study participants will be
located throughout New Zealand (a country of approxi-
mately 1,600 km in length) and for budgetary and logis-
tical reasons it is not possible to conduct face-to-face
verification of their smoking status. Furthermore, bio-
chemical tests which measure cotinine, a metabolite of
nicotine, cannot be used to validate the primary end-
point as a large proportion of control participants will
be using NRT at this time. The Society for Research on
Nicotine and Tobacco reports that the validity of self-
reported smoking status is consistently high in large
population-based studies and that attempts to validate
quit status may introduce a selection bias unrelated to
participants’ smoking status [36].
Current status
The trial started recruiting on the 1st April 2011, with
recruitment expected to take 18 months. Trial findings
are likely to be available late 2013.
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